Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis.

ABSTRACT:

Background

Numerous preclinical studies have revealed a critical role of cysteine-rich 61 (Cyr61) in the pathogenesis of rheumatoid arthritis (RA). But there is little literature discussing the clinical value of circulation Cyr61 in RA patients. The aim of our study is to investigate the serum Cyr61 level and its association with disease activity in RA patients.

Methods

A training cohort was derived from consecutive RA patients who visited our clinic from Jun 2014 to Nov 2018. Serum samples were obtained at the enrollment time. To further confirm discovery, an independent validation cohort was set up based on a registered clinical trial. Paired serum samples of active RA patients were respectively collected at baseline and 12 weeks after uniformed treatment. Serum Cyr61 conc

SUBMITTER: Fan Y 

PROVIDER: S-EPMC6528265 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature